Severe and steroid-resistant Crohn's disease

Area of Science:

• Gastroenterology
• Immunology
• Clinical Medicine

Background:

• Moderate to severe disease management requires distinct approaches.
• Steroid-refractory or -dependent patients often present with less acute conditions.
• Current therapeutic guidelines emphasize specific treatment pathways based on disease severity and response.

Purpose of the Study:

• To delineate management differences between moderate to severe disease and steroid-refractory or -dependent conditions.
• To review first-line and alternative therapies for these patient groups.
• To assess the efficacy of various treatments in achieving steroid-free remission.

Main Methods:

• Review of current clinical practice and therapeutic guidelines.
• Analysis of treatment outcomes for systemic corticosteroids, infliximab, purine analogues, and other immunosuppressors.
• Evaluation of the role of surgery and newer agents like natalizumab.

Main Results:

• Systemic corticosteroids are the primary treatment for moderate to severe disease.
• Infliximab serves as a key alternative for steroid non-responders or contraindications.
• Purine analogues, methotrexate, and infliximab demonstrate effectiveness in achieving steroid-free remission for refractory/dependent cases.

Conclusions:

• Treatment selection is contingent upon disease severity and steroid responsiveness.
• While corticosteroids are foundational, advanced therapies like infliximab and purine analogues are crucial for refractory disease.
• Further research may explore the utility of agents like natalizumab in complex cases.